文献速递肝病

随机临床试验:亮氨酸-二甲双胍-西地那非复方(NS-0200)与非酒精性脂肪性肝病患者的安慰剂对照研究

Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-25

这项2期随机临床试验纳入91例非酒精性脂肪性肝病(NAFLD)患者(MRI-PDFF测得肝脂肪≥15%),随机接受安慰剂、低剂量或高剂量NS-0200(亮氨酸/二甲双胍/西地那非复方)每日两次治疗16周。全队列中活性治疗与安慰剂未分开;高ALT亚组中高剂量NS-0200使肝脂肪较基线相对下降15.7%(P<0.005)。

要点

  • 全队列中低、高剂量NS-0200与安慰剂相比未显示分离。
  • 高ALT亚组(ALT>50 U/L,n=35)中高剂量NS-0200使肝脂肪相对下降15.7%(P<0.005)。
  • 脂质组学显示整体与高ALT队列均存在剂量依赖性治疗效应。

核心结论

  • 数据支持进一步评估高剂量NS-0200用于治疗非酒精性脂肪性肝炎(NASH),尤其在ALT升高者中。

研究设计与样本

  • 2期随机临床试验,纳入91例NAFLD患者(MRI-PDFF肝脂肪≥15%),随机分为安慰剂组、低剂量NS-0200组(亮氨酸1.1 g/二甲双胍0.5 g/西地那非0.5 mg)和高剂量NS-0200组(亮氨酸1.1 g/二甲双胍0.5 g/西地那非1.0 mg),每日两次,疗程16周。
  • 70例完成试验并符合预设依从性标准;分析在全队列及ALT高于中位数(50 U/L,n=35)者中进行。

主要发现

  • 全队列中活性治疗与安慰剂未分离。
  • 高ALT组中高剂量NS-0200使肝脂肪较基线相对下降15.7%(P<0.005),低剂量NS-0200与安慰剂未显著改变肝脂肪。
  • 脂质组学分析显示整体队列与高ALT队列均存在剂量依赖性治疗效应,代谢活跃脂质显著下降、脂肪酸氧化上调。

关键数值与推荐

  • 肝脂肪变化以MRI-PDFF评估,脂质代谢以脂质组学特征变化评估。
  • 高ALT组定义为ALT高于中位数50 U/L(n=35)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sirtuin 1 (Sirt1) is suppressed in non-alcoholic fatty liver disease (NAFLD), while its' stimulation or overexpression results in reduced disease severity in pre-clinical NAFLD models. Leucine allosterically activates Sirt1 and synergise with other Sirt/AMPK/NO pathway activators. We developed a triple combination of leucine, metformin and sildenafil (NS-0200), which was effective in a mouse model of non-alcoholic steatohepatitis (NASH). AIM: To report the results from a Phase 2, randomised clinical trial of of NS-0200 in 91 subjects with NAFLD (liver fat ≥15% by magnetic resonance imaging-proton-density fat fraction (MRI-PDFF)). METHODS: Subjects were randomised to placebo, low-dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil) or high-dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) b.d. for 16 weeks; change in hepatic fat was assessed via MRI-PDFF, and lipid metabolism was assessed via changes in the lipidomic signature. Seventy subjects completed the trial and met a priori compliance criteria. Analyses were conducted on the full cohort and on those with alanine aminotransferase (ALT) values above median (50 U/L; n = 35). RESULTS: In the full cohort, active treatments did not separate from placebo. High dose NS-0200 reduced hepatic fat by 15.7% (relative change from baseline) in the high ALT group (P < 0.005) while low dose NS-0200 and placebo did not significantly change hepatic fat. Lipidomic analysis showed dose-responsive treatment effects in both overall and high ALT cohorts, with significant decreases in metabolically active lipids and up-regulation of fatty acid oxidation. CONCLUSION: These data support further evaluation of high-dose NS-0200 for treating NASH, especially in those with elevated ALT (NCT 02546609).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chalasani N, Vuppalanchi R, Rinella M, et al. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018. PMID: 29696666. doi:10.1111/apt.14674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。